Objective: To gain 'first-in-man' evidence that repeated caloric vestibular stimulation (CVS), a non-invasive form of neuro-modulation, can induce a lasting and clinicallyrelevant reduction in Parkinson's Disease (PD) symptoms.
Introduction
The vestibular system detects linear, angular and gravitational acceleration of the head and plays an important role in the autonomic control of eye movement, posture, gait and egocentric perception (see Smith & Zheng, 2013) . Artificial stimulation of the peripheral balance organs, via either galvanic or thermal current, up-regulates metabolic activity across a range of cortical, striatal and cerebellar brain areas (Lopez, Blanke & Mast, 2012) . The clinical relevance of this metabolic activity has been demonstrated in a number of acquired neurological conditions including hemi-spatial neglect (Wilkinson et al., 2014) , aphasia (Wilkinson, Morris, Milberg & Sakel, 2013) , mania (Levine et al., 2012) , central pain (McGeoch, Williams, Lee & Ramachandran, 2008 ) and post-stroke postural instability (Sturt & Punt, 2013) . Despite these promising results, comparably little investigation has been conducted with individuals who suffer from neuro-degenerative disease.
Recent study has, however, produced growing theoretical interest in the idea that ascending projections from the vestibular brainstem nuclei may provide a therapeutic pathway in Parkinson's Disease (PD). In a recent hemi-parkinsonian rat study, artificial stimulation of the vestibular nerves via transmastodial galvanic current was associated with improved locomotory ability and allied increases in GABA concentration in substantia nigra pars reticulata (Samoudi, Nissbrandt, Dutia & Bergquist, 2012) . In human PD studies, galvanic vestibular stimulation has been shown to spontaneously reduce postural sway (Pal, Rosengren & Colebatch, 2009 ), postural response time (Samoudi, Jivegård, Mulavara, & Bergquist, 2015) and also lead to a quickening of bradykinesic rest-to-active transitions in the wrist and trunk (Pan, Soma, Yamamoto, 2008) . Although these results demonstrate the potential therapeutic value of vestibular stimulation in PD, they were acquired under highly prescribed, controlled laboratory conditions, utilized a narrow range of mostly experimental rather than clinical outcomes, and perhaps most importantly did not show if the effects persisted beyond a few hours. In this brief report, we provide the first evidence, drawn from a single-case study, that repeated sessions of vestibular stimulation can induce durable, clinically meaningful improvements in both the motor and non-motor symptoms of PD.
Participant
The participant, a male, aged 70yrs, was diagnosed with PD 7years prior to study enrolment. At study screening, his predominant symptoms were hypokinesia, rigidity and memory loss although formal testing revealed a far broader range of motor and cognitive difficulties -see baseline data in Table 1 . His medication (stalevo 150mg/25mg/200mg, levodopa 100mg with carbidopa 25mg and entacapone 200mg tablets 3 times per day; pramipexole dihydrochloride 1mg tablets 3 times per day) remained unchanged throughout the study.
Intervention
Vestibular stimulation was induced using a novel, caloric device (Scion Neurostim) comprising a headset fashioned like music headphones with aluminum earpieces that contained a solid-state heater/cooler element which warmed and cooled the external ear canals via controlled, time-varying thermal waveforms (see Figure 1) . One earpiece delivered a cold sawtooth waveform (ear canal temperature to 17 0 C every 2mins) and the other delivered a warm sawtooth (ear canal temperature to 42 0 C every 1 minute). To ensure balanced hemispheric activation over the course of the study (warm currents primarily activate ipsilateral cortex while cold currents primarily 5 activate contralateral cortex) we switched the waveform assigned to each ear every 2 days. Each stimulation session lasted 20mins during which time the patient lay passively supine with his head resting on a wedge-shaped pillow angled at 30 0 . Two sessions, spaced at least 4hrs apart, were administered by the patient (with the help of his wife) twice per day, 5 days per week for 3 months. Sham stimulation was delivered in the first month, followed by 2 months of active stimulation. In the sham condition, the unit was operated in the same way as in the active condition, but no power was delivered to the earpieces. The patient was informed that various doses would be administered over the 3 months, and that although there may be times when temperature changes could be felt in the ear (i.e. in the active condition), this should not be taken as evidence that the device was now any more or less effective. 
Results
As can be seen in Table 1 , improvement was observed across nearly all measures during the active relative to sham phase; mobility and cognition increased 6 dramatically and the patient reported feeling less anxious and able to sleep better.
Consistent with a cumulative effect, the greatest improvement was typically observed during the second month of active stimulation, and was still evident at 5months follow-up. These improvements were too large to attribute to published measurement error and exceeded the statistical criterion for minimal clinically important change (MCID) on the UPDRS motor and ADL sub-scales, Schwab & England ADL scale, and HADS depression scale (MCID criteria were unavailable for the other tests). Table 1 here
Discussion
The favorable outcome in this individual could in theory be explained by coincident change unrelated to the intervention, however both the consistency and scale of change and the fact that it was time-locked to the transition from sham to active stimulation makes this less likely. Although the individual was led to believe that thermal sensations in his ear should not be taken as evidence that the stimulation was now somehow more effective, it is conceivable that the sensation uniquely associated with active stimulation improved his behavioural performance via psychological (i.e.
placebo-based), as opposed to neurological, means. It is, however, difficult to believe that an improvement of this origin would still be evident at both formal assessment and from relatives' testimony 5months later. In line with previous study (Samoudi et al., 2012 (Samoudi et al., , 2015 , we therefore tentatively attribute the effects to a vestibular-based mechanism.
As highlighted by Benninger and Hallett (2015) , the shortcomings of conventional pharmacological therapy coupled with the recent success of deep brain stimulation in advanced PD has raised interest in non-invasive forms of neuro-stimulation, however, there has so far been little evidence from transcranial studies that the reported gains translate to long-lasting improvements in well-being and functional independence. We recognize that the inferential power of the present single-case study is limited, however, the improved response profile demonstrated by the participant, perhaps most notably at 5months follow-up, alludes to a practical patient benefit that, in our opinion, justifies larger-scale investigation. Although the biological basis of recovery was not investigated here, we speculate that the nonmotor gains point to activation of non-dopaminergic pathways and may underline the growing therapeutic relevance of the pedunculopontine nucleus given that it both sends and receives dense projections from areas with known vestibular responses and, when directly activated via deep brain stimulation, has been associated with heightened cognition and arousal (Ballanger et al., 2009 ).
Finally, we note that the potential of CVS to help treat cognitive and motor dysfunction in both acquired and dementing neurological illnesses has long been discussed, however, widespread investigation has been hampered by the reliance on cold-water irrigation of the external ear canal which induces nausea and dizziness and is unsuited for repeated administration. Recent advances in biomedical engineering have, however, led to the development of home-use, solid-state devices which enable the temperature of the waveform to be both varied and tightly controlled which in turn offsets physiological habituation and allows the temperature to be maintained at or above 15 0 C. This temperature is too mild to induce distracting side-effects but is the approximate point at which the vestibular nerves reach asymptote (Reker, 1977) .
These technical developments have enabled CVS to become a tool that is potentially relevant to the management of PD and, given the data reported here, should motivate investigations that move beyond single-case and small-group designs. 
